跳至主要内容
临床试验/JPRN-jRCT2080223598
JPRN-jRCT2080223598已完成Unknown

Extended clinical study of DSP-1958

Dainippon Sumitomo Pharma Co., Ltd.0 个研究点目标入组 96 人开始时间: 2017年7月25日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
入组人数
96

研究概览

简要总结

In conclusion, we evaluated the safety of IV thiotepa HDT prior to autologous HSCT for 41 patients with pediatric solid or brain tumors and 51 patients with malignant lymphoma. There were no new safety concerns.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 2age old 至 ot applicable(—)
性别
All

入选标准

  • 1) Collected adequate dose of hematopoietic stem cells.
  • 2) Ability to understand and the willingness to sign a written informed consent form.
  • 3) Negative pregnancy test.
  • 4) Taking appropriate contraceptive measures.
  • 5) ECOG PS of 0 to 2.
  • 6) Adequate liver function, renal function, and cardiac function.

排除标准

  • 1) Receiving any treatment for primary disease.
  • 2) Received live attenuated vaccines within 90 days.
  • 3) Pregnant or breastfeeding.
  • 4) Uncontrolled intercurrent illness.
  • 5) Patients who are receiving any other investigational agents.
  • 6) Active infection.
  • 7) History of allergic reaction attributed to compounds of similar chemical composition.
  • 8) HIV Ab positive.
  • 9) Planning or received within 14 days to treat hydropericardium, pleural effusion.
  • 10) Patients who had grapefruits or grapefruits juice, or St. John's wort within 13 days.
  • 11) Unsuitable for the clinical trial
  • 12) Unable to receive adequate rehydration and frequent blood transfusion.
  • 13) Received hematopoietic transplantation within 6 months.

研究者

相似试验